Stenson Erin K, Tchou Michael J, Wheeler Derek S
aDivisions of Critical Care Medicine bHospital Medicine, Cincinnati Children's Hospital Medical Center cDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Curr Opin Pediatr. 2017 Jun;29(3):305-310. doi: 10.1097/MOP.0000000000000480.
Herein, we review the current guidelines for the management of children with an acute asthma exacerbation. We focus on management in the emergency department, inpatient, and ICU settings.
The most recent statistics show that the prevalence of asthma during childhood has decreased in certain demographic subgroups and plateaued in other subgroups. However, acute asthma accounts for significant healthcare expenditures. Although there are few, if any, newer therapeutic agents available for management of acute asthma exacerbations, several reports leveraging quality improvement science have shown significant reductions in costs of care as well as improvements in outcome.
Asthma is one of the most common chronic conditions in children and the most common reason that children are admitted to the hospital. Nevertheless, the evidence to support specific agents in the management of acute asthma exacerbations is surprisingly limited. The management of acute exacerbations focuses on reversal of bronchospasm, correction of hypoxia, and prevention of relapse and recurrence. Second-tier and third-tier agents are infrequently used outside of the ICU setting. Reducing the variation in treatment is likely to lead to lower costs and better outcomes.
在此,我们回顾目前关于儿童急性哮喘加重期管理的指南。我们重点关注急诊科、住院部和重症监护病房环境下的管理。
最新统计数据显示,儿童哮喘的患病率在某些人口亚组中有所下降,而在其他亚组中趋于平稳。然而,急性哮喘导致了大量的医疗支出。虽然用于治疗急性哮喘加重期的新型治疗药物很少(如果有的话),但一些利用质量改进科学的报告显示,护理成本显著降低,结果也有所改善。
哮喘是儿童最常见的慢性病之一,也是儿童住院的最常见原因。然而,支持在急性哮喘加重期使用特定药物的证据出奇地有限。急性加重期的管理重点是逆转支气管痉挛、纠正缺氧以及预防复发。在重症监护病房环境之外,二线和三线药物很少使用。减少治疗差异可能会降低成本并改善结果。